Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20602
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSchernthaner, G.en
dc.contributor.authorBarnett, A. H.en
dc.contributor.authorBetteridge, D. J.en
dc.contributor.authorCarmena, R.en
dc.contributor.authorCeriello, A.en
dc.contributor.authorCharbonnel, B.en
dc.contributor.authorHanefeld, M.en
dc.contributor.authorLehmann, R.en
dc.contributor.authorMalecki, M. T.en
dc.contributor.authorNesto, R.en
dc.contributor.authorPirags, V.en
dc.contributor.authorScheen, A.en
dc.contributor.authorSeufert, J.en
dc.contributor.authorSjoholm, A.en
dc.contributor.authorTsatsoulis, A.en
dc.contributor.authorDeFronzo, R.en
dc.date.accessioned2015-11-24T19:08:50Z-
dc.date.available2015-11-24T19:08:50Z-
dc.identifier.issn1432-0428-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20602-
dc.rightsDefault Licence-
dc.subject*Algorithmsen
dc.subjectCardiovascular Diseases/prevention & controlen
dc.subjectDiabetes Mellitus, Type 2/complications/*drug therapyen
dc.subjectEuropeen
dc.subjectHumansen
dc.subjectHyperglycemia/drug therapyen
dc.subjectHypoglycemic Agents/therapeutic useen
dc.subjectRisk Factorsen
dc.subjectSocieties, Medical/standardsen
dc.subjectUnited Statesen
dc.titleIs the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysisen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1007/s00125-010-1702-3-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20352408-
heal.identifier.secondaryhttp://www.springerlink.com/content/11115287k1101761/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2010-
heal.abstractThe ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabetes complications and cardiovascular risk. This paper critically assesses the basis of the ADA/EASD algorithm and the resulting tiers of treatment options.en
heal.journalNameDiabetologiaen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Schernthaner-2010-Is the ADA_EASD algo.pdf241.79 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons